Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

AVE 1330A

Known as: AVE-1330A, AVE1330A 
 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

AzepinesSulfuric Acid Estersbeta-Lactamase Inhibitors

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Ceftazidime/Avibactam: A New Antibiotic for Gram-Negative Infections.
OBJECTIVE To review the chemistry, pharmacology, microbiology, pharmacokinetics, pharmacodynamics, clinical efficacy, safety… Expand
Review
2014
Review
2014
Ceftazidime–avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections
Avibactam (NXL104, AVE1330A) is a semi-synthetic, non-β-lactam, β-lactamase inhibitor that is active against Ambler class A… Expand
  • figure 1
  • figure 2
  • table 2
  • table 3
  • table 4
Review
2013
Review
2013
Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination
Avibactam (formerly NXL104, AVE1330A) is a synthetic non-β-lactam, β-lactamase inhibitor that inhibits the activities of Ambler… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 3
2004
2004
In vitro activity of AVE1330A, an innovative broad-spectrum non-beta-lactam beta-lactamase inhibitor.
OBJECTIVES Production of beta-lactamases is the main mechanism of beta-lactam resistance in Gram-negative bacteria. Despite the… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE